AGRX
Agile Therapeutics Inc
Agile Therapeutics Inc
$AGRX Reports Significant Increase in Net Revenue Due to High Demand for Contraceptive Product, Twirla, in Q1 2023
Agile Therapeutics' Q1 2023 net revenue of $30M represents exceptional growth due to demand for transdermal contraceptive patch, Twirla. The company expects this trend to continue for Q2 2023 while managing operating expenses. Agile Therapeutics prioritizes freedom in contraceptive options beyond daily pills and partners with Afaxys and Nurx to promote growth and educate patients respectively. Though Agile Therapeutics faces regulatory, supply chain, and compliance risks, they remain optimistic about future prospects. Their presentation of non-GAAP financial metrics provides meaningful supplemental information to investors.
16d ago
$AGRXAgile Therapeutics Inc
$AGRX reports positive Q1 2023 financial results with continued growth momentum and strong demand for contraceptive patch product, Twirla.
Agile Therapeutics' Q1 2023 report shows growth in net revenue and operating expenses, with expectations to continue in Q2 2023. Twirla, its contraceptive patch, has increased steady sales and shows strong demand. Agile Therapeutics plans to use telehealth collaboration to drive retail growth in H2 2023. They aim to expand markets and serve women seeking contraceptive options. Potential risks and uncertainties related to regulations and COVID-19 are noted but Agile Therapeutics remains an attractive investment for growth performance.
29d ago
$AGRX